Does B-type natriuretic peptide-guided therapy improve outcomes in patients with chronic heart failure? A systematic review and meta-analysis of randomized controlled trials (original) (raw)
References
McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, Falk V, Filippatos G, Fonseca C, Gomez-Sanchez MA, Jaarsma T, Kober L, Lip GY, Maggioni AP, Parkhomenko A, Pieske BM, Popescu BA, Ronnevik PK, Rutten FH, Schwitter J, Seferovic P, Stepinska J, Trindade PT, Voors AA, Zannad F, Zeiher A (2012) ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 33(14):1787–1847. doi:10.1093/eurheartj/ehs104 ArticlePubMed Google Scholar
Yancy CW, Jessup M, Bozkurt B, Masoudi FA, Butler J, McBride PE, Casey DE Jr, McMurray JJ, Drazner MH, Mitchell JE, Fonarow GC, Peterson PN, Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Riegel B, Sam F, Stevenson LW, Tang WH, Tsai EJ, Wilkoff BL (2013) 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. doi:10.1016/j.jacc.2013.05.019 PubMed Central Google Scholar
Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Borden WB, Bravata DM, Dai S, Ford ES, Fox CS, Franco S, Fullerton HJ, Gillespie C, Hailpern SM, Heit JA, Howard VJ, Huffman MD, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH, Lisabeth LD, Magid D, Marcus GM, Marelli A, Matchar DB, McGuire DK, Mohler ER, Moy CS, Mussolino ME, Nichol G, Paynter NP, Schreiner PJ, Sorlie PD, Stein J, Turan TN, Virani SS, Wong ND, Woo D, Turner MB (2013) Heart disease and stroke statistics—2013 update: a report from the American Heart Association. Circulation 127(1):e6–e245. doi:10.1161/CIR.0b013e31828124ad ArticlePubMed Google Scholar
Heidenreich PA, Albert NM, Allen LA, Bluemke DA, Butler J, Fonarow GC, Ikonomidis JS, Khavjou O, Konstam MA, Maddox TM, Nichol G, Pham M, Pina IL, Trogdon JG (2013) Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association. Circ Heart Fail 6(3):606–619. doi:10.1161/HHF.0b013e318291329a ArticleCASPubMed CentralPubMed Google Scholar
Komajda M, Lapuerta P, Hermans N, Gonzalez-Juanatey JR, van Veldhuisen DJ, Erdmann E, Tavazzi L, Poole-Wilson P, Le Pen C (2005) Adherence to guidelines is a predictor of outcome in chronic heart failure: the MAHLER survey. Eur Heart J 26(16):1653–1659. doi:10.1093/eurheartj/ehi251 ArticlePubMed Google Scholar
Calvin JE, Shanbhag S, Avery E, Kane J, Richardson D, Powell L (2012) Adherence to evidence-based guidelines for heart failure in physicians and their patients: lessons from the Heart Failure Adherence Retention Trial (HART). Congest Heart Fail 18(2):73–78. doi:10.1111/j.1751-7133.2011.00263.x ArticlePubMed Google Scholar
Yancy CW, Fonarow GC, Albert NM, Curtis AB, Stough WG, Gheorghiade M, Heywood JT, McBride ML, Mehra MR, O’Connor CM, Reynolds D, Walsh MN (2010) Adherence to guideline-recommended adjunctive heart failure therapies among outpatient cardiology practices (findings from IMPROVE HF). Am J Cardiol 105(2):255–260. doi:10.1016/j.amjcard.2009.08.681 ArticlePubMed Google Scholar
Troughton RW, Richards AM, Yandle TG, Frampton CM, Nicholls MG (2007) The effects of medications on circulating levels of cardiac natriuretic peptides. Ann Med 39(4):242–260. doi:10.1080/07853890701232057 ArticleCASPubMed Google Scholar
Latini R, Masson S, Anand I, Judd D, Maggioni AP, Chiang YT, Bevilacqua M, Salio M, Cardano P, Dunselman PH, Holwerda NJ, Tognoni G, Cohn JN (2002) Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: the Valsartan Heart Failure Trial (Val-HeFT). Circulation 106(19):2454–2458 ArticleCASPubMed Google Scholar
Verdiani V, Ognibene A, Rutili MS, Lombardo C, Bacci F, Terreni A, Nozzoli C (2008) NT-ProBNP reduction percentage during hospital stay predicts long-term mortality and readmission in heart failure patients. J Cardiovasc Med (Hagerstown) 9(7):694–699. doi:10.2459/JCM.0b013e3282f447ae Article Google Scholar
Troughton RW, Frampton CM, Yandle TG, Espiner EA, Nicholls MG, Richards AM (2000) Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 355(9210):1126–1130 ArticleCASPubMed Google Scholar
Beck-da-Silva L, de Bold A, Fraser M, Williams K, Haddad H (2005) BNP-guided therapy not better than expert’s clinical assessment for beta-blocker titration in patients with heart failure. Congest Heart Fail 11(5):248–253 (quiz 254–245) ArticleCASPubMed Google Scholar
Jourdain P, Jondeau G, Funck F, Gueffet P, Le Helloco A, Donal E, Aupetit JF, Aumont MC, Galinier M, Eicher JC, Cohen-Solal A, Juilliere Y (2007) Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP Multicenter Study. J Am Coll Cardiol 49(16):1733–1739. doi:10.1016/j.jacc.2006.10.081 ArticleCASPubMed Google Scholar
Lainchbury JG, Troughton RW, Strangman KM, Frampton CM, Pilbrow A, Yandle TG, Hamid AK, Nicholls MG, Richards AM (2009) N-terminal pro-B-type natriuretic peptide-guided treatment for chronic heart failure: results from the BATTLESCARRED (NT-proBNP-assisted treatment to lessen serial cardiac readmissions and death) trial. J Am Coll Cardiol 55(1):53–60. doi:10.1016/j.jacc.2009.02.095 ArticlePubMed Google Scholar
Pfisterer M, Buser P, Rickli H, Gutmann M, Erne P, Rickenbacher P, Vuillomenet A, Jeker U, Dubach P, Beer H, Yoon SI, Suter T, Osterhues HH, Schieber MM, Hilti P, Schindler R, Brunner-La Rocca HP (2009) BNP-guided vs symptom-guided heart failure therapy: the trial of intensified vs standard medical therapy in elderly patients with congestive heart failure (TIME-CHF) randomized trial. JAMA 301(4):383–392. doi:10.1001/jama.2009.2 ArticleCASPubMed Google Scholar
Eurlings LW, van Pol PE, Kok WE, van Wijk S, Lodewijks-van der Bolt C, Balk AH, Lok DJ, Crijns HJ, van Kraaij DJ, de Jonge N, Meeder JG, Prins M, Pinto YM (2010) Management of chronic heart failure guided by individual N-terminal pro-B-type natriuretic peptide targets: results of the PRIMA (Can PRo-brain-natriuretic peptide guided therapy of chronic heart failure IMprove heart failure morbidity and mortality?) study. J Am Coll Cardiol 56(25):2090–2100. doi:10.1016/j.jacc.2010.07.030 ArticleCASPubMed Google Scholar
Persson H, Erntell H, Eriksson B, Johansson G, Swedberg K, Dahlstrom U (2010) Improved pharmacological therapy of chronic heart failure in primary care: a randomized Study of NT-proBNP Guided Management of Heart Failure—SIGNAL-HF (Swedish Intervention study—Guidelines and NT-proBNP Analysis in Heart Failure). Eur J Heart Fail 12(12):1300–1308. doi:10.1093/eurjhf/hfq169 ArticleCASPubMed Google Scholar
Berger R, Moertl D, Peter S, Ahmadi R, Huelsmann M, Yamuti S, Wagner B, Pacher R (2010) N-terminal pro-B-type natriuretic peptide-guided, intensive patient management in addition to multidisciplinary care in chronic heart failure a 3-arm, prospective, randomized pilot study. J Am Coll Cardiol 55(7):645–653. doi:10.1016/j.jacc.2009.08.078 ArticleCASPubMed Google Scholar
Anguita M, Esteban F, Castillo JC, Mazuelos F, Lopez-Granados A, Arizon JM, Suarez De Lezo J (2010) Usefulness of brain natriuretic peptide levels, as compared with usual clinical control, for the treatment monitoring of patients with heart failure. Med Clin (Barc) 135(10):435–440. doi:10.1016/j.medcli.2009.11.048 Article Google Scholar
Januzzi JL Jr, Rehman SU, Mohammed AA, Bhardwaj A, Barajas L, Barajas J, Kim HN, Baggish AL, Weiner RB, Chen-Tournoux A, Marshall JE, Moore SA, Carlson WD, Lewis GD, Shin J, Sullivan D, Parks K, Wang TJ, Gregory SA, Uthamalingam S, Semigran MJ (2011) Use of amino-terminal pro-B-type natriuretic peptide to guide outpatient therapy of patients with chronic left ventricular systolic dysfunction. J Am Coll Cardiol 58(18):1881–1889. doi:10.1016/j.jacc.2011.03.072 ArticleCASPubMed Google Scholar
Karlstrom P, Alehagen U, Boman K, Dahlstrom U (2011) Brain natriuretic peptide-guided treatment does not improve morbidity and mortality in extensively treated patients with chronic heart failure: responders to treatment have a significantly better outcome. Eur J Heart Fail 13(10):1096–1103. doi:10.1093/eurjhf/hfr078 ArticlePubMed Google Scholar
Shah MR, Califf RM, Nohria A, Bhapkar M, Bowers M, Mancini DM, Fiuzat M, Stevenson LW, O’Connor CM (2011) The STARBRITE trial: a randomized, pilot study of B-type natriuretic peptide-guided therapy in patients with advanced heart failure. J Card Fail 17(8):613–621. doi:10.1016/j.cardfail.2011.04.012 ArticlePubMed Google Scholar
Schou M, Gustafsson F, Videbaek L, Andersen H, Toft J, Nyvad O, Ryde H, Fog L, Jensen JC, Nielsen OW, Lind-Rasmussen S, Abdulla J, Hildebrandt PR (2013) Adding serial N-terminal pro brain natriuretic peptide measurements to optimal clinical management in outpatients with systolic heart failure: a multicentre randomized clinical trial (NorthStar monitoring study). Eur J Heart Fail 15(7):818–827. doi:10.1093/eurjhf/hft037 ArticleCASPubMed Google Scholar
Maeder MT, Rickenbacher P, Rickli H, Abbuhl H, Gutmann M, Erne P, Vuilliomenet A, Peter M, Pfisterer M, Brunner-La Rocca HP (2013) N-terminal pro brain natriuretic peptide-guided management in patients with heart failure and preserved ejection fraction: findings from the Trial of Intensified versus standard Medical therapy in Elderly patients with Congestive Heart Failure (TIME-CHF). Eur J Heart Fail. doi:10.1093/eurjhf/hft076 Google Scholar
Higgins J, Green S (2011) Cochrane handbook for systematic reviews of interventions version 5.1.0. The Cochrane Collaboration. www.cochranehandbook.org
Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315(7109):629–634 ArticleCASPubMed CentralPubMed Google Scholar
Felker GM, Hasselblad V, Hernandez AF, O’Connor CM (2009) Biomarker-guided therapy in chronic heart failure: a meta-analysis of randomized controlled trials. Am Heart J 158(3):422–430. doi:10.1016/j.ahj.2009.06.018 ArticleCASPubMed Google Scholar
Li P, Luo Y, Chen YM (2013) B-type natriuretic peptide-guided chronic heart failure therapy: a meta-analysis of 11 randomised controlled trials. Heart Lung Circ. doi:10.1016/j.hlc.2013.03.077 Google Scholar
Savarese G, Trimarco B, Dellegrottaglie S, Prastaro M, Gambardella F, Rengo G, Leosco D, Perrone-Filardi P (2013) Natriuretic peptide-guided therapy in chronic heart failure: a meta-analysis of 2,686 patients in 12 randomized trials. PLoS ONE 8(3):e58287. doi:10.1371/journal.pone.0058287 ArticleCASPubMed CentralPubMed Google Scholar
Troughton RW, Frampton CM, Brunner-La Rocca HP, Pfisterer M, Eurlings LW, Erntell H, Persson H, O’Connor CM, Moertl D, Karlstrom P, Dahlstrom U, Gaggin HK, Januzzi JL, Berger R, Richards AM, Pinto YM, Nicholls MG (2014) Effect of B-type natriuretic peptide-guided treatment of chronic heart failure on total mortality and hospitalization: an individual patient meta-analysis. Eur Heart J. doi:10.1093/eurheartj/ehu090 PubMed Central Google Scholar
Troughton RW, Prior DL, Pereira JJ, Martin M, Fogarty A, Morehead A, Yandle TG, Richards AM, Starling RC, Young JB, Thomas JD, Klein AL (2004) Plasma B-type natriuretic peptide levels in systolic heart failure: importance of left ventricular diastolic function and right ventricular systolic function. J Am Coll Cardiol 43(3):416–422. doi:10.1016/j.jacc.2003.08.046 ArticleCASPubMed Google Scholar
Kubanek M, Malek I, Bytesnik J, Fridl P, Riedlbauchova L, Karasova L, Lanska V, Kautzner J (2006) Decrease in plasma B-type natriuretic peptide early after initiation of cardiac resynchronization therapy predicts clinical improvement at 12 months. Eur J Heart Fail 8(8):832–840. doi:10.1016/j.ejheart.2006.02.006 ArticleCASPubMed Google Scholar
Brunner-La Rocca HP, Weilenmann D, Kiowski W, Maly FE, Candinas R, Follath F (1999) Within-patient comparison of effects of different dosages of enalapril on functional capacity and neurohormone levels in patients with chronic heart failure. Am Heart J 138(4 Pt 1):654–662 ArticleCASPubMed Google Scholar
Yoshimura M, Mizuno Y, Nakayama M, Sakamoto T, Sugiyama S, Kawano H, Soejima H, Hirai N, Saito Y, Nakao K, Yasue H, Ogawa H (2002) B-type natriuretic peptide as a marker of the effects of enalapril in patients with heart failure. Am J Med 112(9):716–720 ArticleCASPubMed Google Scholar
Savarese G, Musella F, D’Amore C, Vassallo E, Losco T, Gambardella F, Cecere M, Petraglia L, Pagano G, Fimiani L, Rengo G, Leosco D, Trimarco B, Perrone-Filardi P (2014) Changes of natriuretic peptides predict hospital admissions in patients with chronic heart failure: a meta-analysis. JACC Heart Fail 2(2):148–158. doi:10.1016/j.jchf.2013.11.007 ArticlePubMed Google Scholar
Gaggin HK, Mohammed AA, Bhardwaj A, Rehman SU, Gregory SA, Weiner RB, Baggish AL, Moore SA, Semigran MJ, Januzzi JL Jr (2012) Heart failure outcomes and benefits of NT-proBNP-guided management in the elderly: results from the prospective, randomized ProBNP outpatient tailored chronic heart failure therapy (PROTECT) study. J Card Fail 18(8):626–634. doi:10.1016/j.cardfail.2012.05.005 ArticleCASPubMed Google Scholar